Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

C. Scheid, P. Sonneveld, I.G.H. Schmidt-Wolf, B. van der Holt, L. el Jarari, U. Bertsch, H. Salwender, S. Zweegman, I.W. Blau, E. Vellenga, K. Weisel, M. Pfreundschuh, K.S. Jie, K. Neben, H. van der Velde, U. Duehrsen, M.R. Schaafsma, W. Lindemann, M.J. Kersten, N. PeterM. Hanel, S. Croockewit, H. Martin, S. Wittebol, G.M.J. Bos, M. van Marwijk-Kooy, P. Wijermans, H. Goldschmidt, H.M. Lokhorst

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)148-154
JournalHaematologica
Volume99
Issue number1
DOIs
Publication statusPublished - 2014

Cite this